Last updated: 2026-09-09 09:43:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Scholar Rock Holding Corporation (SRRK) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $57.41, with a market capitalization of $6.74B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $27.07 to $61.76. This page covers its latest market performance, valuation, price trends and company information.
$6.74B | |
$57.78 | |
$70.00 | |
$4.33 | |
$57.42 | |
-- | |
1.32M | |
-- | |
$61.76 | |
$27.07 | |
-- | |
-- |
Scholar Rock Holding Corporation (SRRK) is trading at $57.41 in pre-market trading as of 2026-09-09 09:25:00, down 0.01% ($0.01) from the previous close of $57.42
Pre-market trading shows how investors are pricing SRRK before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Scholar Rock Holding Corporation (SRRK) moved from $57.80 to $57.41, representing a decline of 0.67% ($0.39).
The stock traded between $54.00 and $59.30 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 989.12 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 87.5%
SRRK is currently trading at $57.41, placing it 87.5% of the way from its 52-week low of $27.07 to its 52-week high of $61.76. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 289 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Scholar Rock Holding Corporation (SRRK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.